Lysophosphatidic Acid Promotes Expression and Activation of Matrix Metalloproteinase 9 (MMP9) in THP-1 Cells via Toll-Like Receptor 4/Nuclear Factor-κB (TLR4/NF-κB) Signaling Pathway

Background: Lysophosphatidic acid (LPA) is an active compound of oxidized low-density lipoprotein that serves as an en dogenous TLR4 ligand. Ligand activation of TLR4 activates nuclear factor-kappaB (NF-kappa B) and the transcription of NF-kappa B-regulated inflammatory cytokines, which are involved in the development of atherosclerosis. MMP9 is a member of the MMP family and can affect plaque stability. However, the mechanism responsible for the effect of LPA on the expression and activation of MMP9 has not been fully elucidated. In the present study we examined the effect of LPA on MMP9 expression and activity in THP-1 cells and the involvement of Toll-like receptor 4/nuclear factor-kappa B (TLR4/NF-kappa B) signaling pathway in this effect. Material/Methods: Human THP-1 cells were treated with 0-10 mu M LPA for 4 h, or treated with 1 mu M LPA for 0-8 h, and were then transfected with TLR4-specific siRNA or treated with 20 mu g/ml cafestol acid phenethyl ester (CAPE, an NE-kappa B inhibitor). MMP9 mRNA and protein levels were measured by quantitative RT-PCR and Western blot analysis, respectively, and MMP9 activity was measured by zymography. Results: LPA upregulated MMP9 mRNA and protein levels and MMP9 activity in THP-1 cells in both concentration- and time-dependent manners. Transfection of cells with TLR4-siRNA-2 or treatment with CAPE significantly inhibited the upregulated MMP9 expression and activation. This inhibition was further enhanced by combining the TLR4-siRNA-2 transfection and CAPE pretreatment. Conclusions: LPA can promote MMP9 expression and enhance MMP9 activity in THP-1 cells, in part via the TLR4/NF-kappa B signaling pathway.